
Trump's budget cuts may hand Spain a scientific prize worth billions
As the U.S. backs away from key climate, aid, and scientific investments, Europe is stepping in to pick up the slack.
Europe's latest intervention? Saving a plan to build one of the world's largest, cutting-edge telescopes. This week, the Spanish government offered to pay $470 million to take over one of the most ambitious astronomy projects in history, known as the Thirty Meter Telescope (TMT). In the deal, Spain would also provide the unconstructed mega-telescope a home atop a rugged peak on La Palma, one of the Canary Islands off the coast of Africa.
After massive proposed cuts to the National Science Foundation's $9 billion budget, the project faced a financing shortfall that likely spelled its doom. Trump's cuts, detailed in late May, slash the foundation's budget by more than half, jettisoning funding for the TMT while keeping another $3 billion telescope project, the Giant Magellan Telescope (GMT) – under construction now in Chile – alive.
'Faced with the risk of this major international scientific project being halted, the Government of Spain has decided to act with renewed commitment to science and major scientific infrastructures for the benefit of global knowledge,' Spain's Minister of Science, Innovation and Universities Diana Morant said.
When constructed, the telescope will be a modern scientific marvel. Named the Thirty Meter Telescope for the size of its mirror, the project was designed to take on some of astronomy's most compelling questions, searching the deep skies for signs of extraterrestrial life, evidence of the universe's origins and clues about the nature of dark matter. Compared to images from the James Webb Space Telescope, a triumph of engineering itself, the TMT will produce images four times sharper.
A controversial telescope
Pondering the universe's biggest mysteries is a shared human experience, but the TMT's journey to investigate them has proven surprisingly divisive.
The plan to build a mega-telescope with a mirror as big as a blue whale began in 2003. The project evolved over time into a consortium of scientists from around the globe, an organization now known as the TMT International Observatory (TIO). The group determined that the ideal site for the massive lens was the summit of Hawaii's highest peak, Mauna Kea.
While Mauna Kea's high, dry summit attracts astronomy projects and already hosts thirteen other telescopes, the peak's history as a sacred place in Hawaiian culture prompted a public outcry from residents and conservationists who wanted the TMT built elsewhere. The mountain is known as the home of the god Wakea and plays a central role in native Hawaiian creation stories, a status that inspired a resistance movement against plans to further develop the area.
It's not the project's first pick, but Spain's offer to host the project is a natural fit. The Spanish island of La Palma was already the telescope's backup plan, and like Mauna Kea it offers a remote, high perch with consistently clear skies and infrastructure already in place from other international observatories.
'In 2019, the Government of Spain already expressed its willingness for the TMT to be built on this island, and now, six years later, it is taking a decisive step with a strategic investment that will benefit the European Union, Spain, the Canary Islands, and especially La Palma,' Spain's Ministry of Science, Innovation and Universities said.
Trump-era cuts to science funding weren't the first time that the U.S. budget imperiled at least one of the two major next-generation telescopes in the works. With the GMT still on track, its counterpart might have a brighter future under an eager government across the ocean.
'While some countries are cutting science investments and even denying it, Spain is a refuge for science,' Morant said.
The super-early-rate deadline for Fast Company's Most Innovative Companies Awards is tonight, July 25, at 11:59 p.m. PT. Apply today.
ABOUT THE AUTHOR
Taylor Hatmaker is a writer and photographer based on the West Coast. She was previously a Senior Editor at TechCrunch, where she specialized in social media, gaming and online culture. More
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
4 hours ago
- Associated Press
Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference
LOS ANGELES--(BUSINESS WIRE)--Aug 4, 2025-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit Mr. Fried and Mr. Pamir will also hold one-on-one meetings with institutional investors throughout the conference. To arrange a meeting, please visit the conference website here or contact your CG representative. A replay of the fireside chat webcast will be available on the Niagen Bioscience Investor Relations website, following the event. For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen ®, the number one NAD+ boosting oral supplement in the United States † (available at ), and Niagen Plus ™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). View source version on CONTACT: Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310.405.5227 [email protected] Bioscience Investor Relations Contact: ICR, LLC Reed Anderson (646) 277-1260 Stephanie Carrington (646) 277-1282 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH SCIENCE PHARMACEUTICAL RESEARCH SOURCE: Niagen Bioscience, Inc Copyright Business Wire 2025. PUB: 08/04/2025 08:32 AM/DISC: 08/04/2025 08:32 AM


Medscape
5 hours ago
- Medscape
Non-Invasive Test May Transform Infant Meningitis Screening
TOPLINE: A high-resolution ultrasound-based device demonstrated excellent accuracy in detecting elevated white blood cell (WBC) counts in cerebrospinal fluids, showing promise as a non-invasive screening tool for meningitis in neonates and infants with a permeable fontanel and potentially offering an alternative to lumbar puncture. METHODOLOGY: The diagnosis of meningitis requires an invasive lumbar puncture to collect cerebrospinal fluid for detecting elevated WBC counts; however, this procedure carries inherent risks and practical limitations. Researchers conducted a prospective study across hospitals in Spain, Mozambique, and Morocco to validate the safety and accuracy of Neosonics — a non-invasive high-resolution ultrasound-based device that can detect signals from WBCs in the cerebrospinal fluid via the anterior fontanel — in neonates and infants younger than 24 months with suspected meningitis against the gold-standard techniques. High-resolution images of the cerebrospinal fluid were captured and used to train a deep learning model that identified and classified cerebrospinal fluid patterns on the basis of lumbar puncture-confirmed WBC counts, with ≥ 30 cells/mm 3 defined as a case. defined as a case. The accuracy of the trained algorithm was tested on 3782 high-resolution images of 76 patients. TAKEAWAY: The Neosonics device correctly identified 17 of 18 meningitis cases and 55 of 58 controls participants without meningitis, yielding a sensitivity of 94.4% and a specificity of 94.8%. Overall, the device achieved an accuracy of 94.7% in detecting elevated WBC counts in the cerebrospinal fluid. Misclassified participants either had low WBC counts or were microbiologically confirmed cases without elevated WBC counts. IN PRACTICE: "The non-invasive WBC counter, can lead to a more accurate indication for LP [lumbar puncture] and/or indications of treatment, resulting in better patient outcomes and in a reduction of the risk of long-term sequelae, along with a likely more cost-effective use of resources in all settings," the authors wrote. SOURCE: This study was led by Sara Ajanovic and Quique Bassat, ISGlobal, Barcelona, Spain, and Fernando Cabañas, Quirónsalud Madrid University Hospital, Madrid, Spain. It was published online on July 23, 2025, in Pediatric Research. LIMITATIONS: This study faced challenges in obtaining reliable gold-standard comparison results. The device's precision decreased in participants with thicker fontanels, and it misclassified three participants with very narrow cerebrospinal fluid spaces. Moreover, the image acquisition time was suboptimal. DISCLOSURES: This study was supported, in whole or in part, by the Gates Foundation in Mozambique and Morocco; funded by Instituto de Salud Carlos III and co-funded by the European Union in Spain; and funded by the Spanish Agency of Cooperation in Morocco. Five authors were employees of Kriba, the company developing Neosonics. One author and the ISGlobal Biomedical Data Science team disclosed receiving honoraria, training fees, and consulting fees from Kriba. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Yahoo
12 hours ago
- Yahoo
Glacier retreat on Heard Island
The video shows the difference in ice cover between 1947, 1988 and 2019. Source: Monash University/Google Earth